Close Menu

Hematology/Coagulation

News on hematology and coagulation testing systems and applications.

The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.

The ID Core XT is the second molecular assay approved by the FDA for use in transfusion medicine and the first to report genotypes as final results.

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

The test reduces hands-on time by enabling labs to simultaneously assess Factor II and Factor V gene mutations from a single patient sample, Roche said.

The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.

Jan
28
Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.